Table 2.
Results from the clinical and laboratory tests throughout the study
| Clinical and laboratory parameters | Therapeutic drug programme | 0 months | 3 months | 6 months | 9 months | 12 months | p a |
|---|---|---|---|---|---|---|---|
| GFR (ml/min per 1.73 m2) | MMF | 125 (34) | 123 (33) | 126 (26) | 125 (31) | 131 (40) | 0.03 |
| CsA | 123 (22) | 112 (26) | 107 (16) | 114 (18) | 109 (16) | ||
| Systolic blood pressure (SDS) | MMF | 1.04 (0.89) | 0.87 (0.84) | 0.61 (0.83) | 0.89 (0.68) | 0.62 (0.71) | 0.17 |
| CsA | 1.35 (0.93) | 1.19 (0.56) | 1.13 (0.78) | 1.17 (1.05) | 0.88 (1.16) | ||
| Diastolic blood pressure (SDS) | MMF | 0.36 (0.77) | 0.44 (0.80) | 0.22 (0.63) | 0.27 (0.71) | 0.05 (0.68) | 0.57 |
| CsA | 0.21 (0.83) | −0.05 (0.77) | 0.00 (0.72) | 0.12 (0.89) | 0.30 (0.91) | ||
| Haemoglobin (g/dl) | MMF | 13.5 (1.1) | 13.2 (1.0) | 13.0 (1.4) | 13.0 (1.0) | 13.5 (1.1) | 0.005 |
| CsA | 13.0 (1.3) | 12.2 (0.6) | 12.0 (0.3) | 11.9 (0.8) | 12.0 (1.0) | ||
| Leucocytes (×1000 cells/mm3) | MMF | 7.3 (2.6) | 6.7 (1.9) | 7.4 (3.9) | 6.5 (2.1) | 6.1 (1.7) | 0.43 |
| CsA | 8.1 (2.8) | 7.0 (1.7) | 7.7 (2.2) | 7.7 (2.6) | 8.1 (3.0) | ||
| Lymphocytes (×1000 cells/mm3) | MMF | 2.5 (1.3) | 2.5 (0.9) | 2.0 (0.9) | 2.0 (0.9) | 2.0 (0.7) | 0.99 |
| CsA | 2.8 (1.2) | 2.3 (0.6) | 2.3 (0.8) | 2.0 (0.8) | 2.3 (0.5) | ||
| Cholesterol (mg/dl) | MMF | 196 (81) | 181 (89) | 0.59 | |||
| CsA | 181 (42) | 177 (31) | |||||
| Triglycerides (mg/dl) | MMF | 114 (50) | 84 (30) | 0.59 | |||
| CsA | 114 (50) | 85 (40) | |||||
| LDL-cholesterol (mg/dl) | MMF | 104 (23) | 85 (19) | 0.10 | |||
| CsA | 112 (46) | 116 (35) | |||||
| HDL-cholesterol (mg/dl) | MMF | 58 (15) | 54 (8) | 0.60 | |||
| CsA | 54 (12) | 58 (12) |
All values are means, with the standard deviation given in parenthesis
GFR, Glomerular filtration rate; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol
aThe p value compares the overall change from baseline between the two groups